We are excited to announce the opening and enrollment of patients across the US for our clinical study in newly diagnosed glioblastoma patients. Our current open sites can be found on clinicaltrials.gov. Learn more about our study at https://lnkd.in/d-QYVsWk #ClinicalStudy #Glioblastoma #PatientEnrollment #ResearchOpportunity #Healthcare #Innovation https://lnkd.in/dgZKvEKS
TVAX Biomedical, Inc.
Biotechnology Research
Lenexa, KS 354 followers
Vaccine-enhanced adoptive T cell immunotherapy ...developing an immune response against one's own tumor.
About us
TVAX Biomedical is a biotechnology company currently performing phase 2b/3 clinical trials to test a unique cancer immunotherapy as a treatment for pediatric brain cancer.
- Website
-
http://tvaxbiomedical.com
External link for TVAX Biomedical, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Lenexa, KS
- Type
- Privately Held
- Specialties
- Immunotherapy, Cancer, glioma, Pediatric glioma, T cell, T cell therapy, Cancer immunotherapy, Pediatric high grade glioma, and Oncology
Locations
-
Get directions
8006 Reeder Street
Lenexa, KS 66214, US
Employees at TVAX Biomedical, Inc.
Updates
-
VERY exciting news from our sister company ELIAS Animal Health! TVAX Biomedical licensed our adoptive T cell technology to ELIAS Animal Health for treatment of cancer in animals. ELIAS Animal Health just received notification from the USDA of approval of their therapy for treatment of dogs with osteosarcoma. A true win-win-win for dogs, pet owners and veterinarians to have a state-of-the-art cellular therapy to treat a deadly aggressive cancer! https://lnkd.in/erntztDK
We are thrilled to announce the achievement of this critical milestone for our first-in-class cancer therapeutic. Our passion for improving cancer treatment options available to the veterinary market through the advancement of innovative therapies has never been stronger! Learn more about ELIAS at https://lnkd.in/gPri67_D #cancerimmunotherapy #cancertreatment #cancersucks #companionanimals
USDA Agrees Clinical Trial Data for the ELIAS Cancer Immunotherapy (ECI®) Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs
prnewswire.com